Yeast beta-glucan emulsions, methods and uses thereof
Yeast β-glucan emulsions formulated with emollients provide effective antiviral protection against herpes simplex virus infections by enhancing skin permeability and inducing an immune response in topical facial compositions.
Patent Information
- Application Number
- JP2023530662
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-12-23
- Filing Date
- 2022-12-21
- Publication Date
- 2024-12-04
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Existing treatments for herpes simplex virus infections on the lips and face areas are inadequate, particularly in topical formulations like lipsticks, face sticks, and balms.
Development of yeast β-glucan emulsions, insoluble in water, formulated with emollients such as squalane, butter, or their mixtures, for use in anti-herpetic facial compositions like lipsticks, face sticks, and balms, which are administered topically to prevent and treat herpes simplex virus infections.
The yeast β-glucan emulsions demonstrate antiviral activity by inducing an immune response and preventing cell death in infected cells, enhancing skin permeability and maintaining anti-herpes efficacy.
Smart Images

Figure 2024544743000002 
Figure 2024544743000003 
Figure 2024544743000004
Abstract
Description
[Technical field]
[0001] The present disclosure relates to emulsions of yeast β-glucan having anti-herpes activity, in particular topical facial compositions, more particularly lipsticks / face sticks / lip balms or face balms / roll ons having anti-herpes properties, methods for obtaining them and their uses.
[0002] The present disclosure also relates to topical facial compositions, preferably anti-herpes active lipsticks or face sticks or anti-herpes lip or face balms or anti-herpes roll-ons, comprising β-glucan and to the use of said compositions for the prevention and treatment of lesions of the lips and other areas of the face caused by the human herpes simplex virus. [Background technology]
[0003] Glucans are polysaccharides present in a variety of organisms, from plants to mushrooms and even fungi such as yeast. In Saccharomyces species, glucans are the major constituent of the cell wall. β-glucans are a specific type of glucan composed of d-glucose units linked by glycosidic bonds β-(1-3);(1-6). This specific type of glucan has interesting biological activities. Many studies have demonstrated β-glucan activities such as anti-wrinkle activity, antioxidant activity and hydration, skin care applications, tissue regeneration, activity against viral infections, and immune stimulating activity such as pro-inflammatory effects. β-glucans can induce immune responses by interacting with pattern recognition receptors expressed by immune cells. One example of immune response induction by β-glucans is the ability of β-glucans to induce innate immune responses by interacting with the Dectin-1 receptor.
[0004] These items are disclosed to illustrate the technical problem solved by the present disclosure. Summary of the Invention [Problem to be solved by the invention]
[0005] The present disclosure relates to an anti-herpes emulsion comprising β-glucan and to the use of said emulsion for the prevention and treatment of lesions of the lips and other areas of the face caused by the human herpes simplex virus.
[0006] One aspect of the present disclosure relates to an emulsion of yeast β-glucan for the prevention or treatment of herpes simplex virus infection, the emulsion comprising an emollient, preferably selected from squalane, butter, hemp oil, or mixtures thereof.
[0007] Another aspect of the present disclosure relates to an emulsion of yeast β-glucan for the prevention or treatment of herpes simplex virus infection, the emulsion comprising 30-80% (w / w) of an emollient; Yeast β-glucan emulsion is an antiviral agent, The amount of β-glucan is in the range of 4 to 25% (w / w), preferably 5 to 25% (w / w).
[0008] In one embodiment, the yeast β-glucan emulsion of the present disclosure can be used to prevent and treat lip disease or herpes simplex virus infections on the lips or other areas of the face affected by human herpes viruses.
[0009] In one embodiment, the yeast β-glucan emulsion of the present disclosure can be administered in the form of a topical facial composition, preferably in the form of an anti-herpes lipstick, face stick, lip balm, face balm, or roll-on.
[0010] In one embodiment, the yeast β-glucan emulsion of the present disclosure is insoluble in water.
[0011] In one embodiment, the yeast β-glucan emulsion of the present disclosure may be a native β-glucan.
[0012] In one embodiment, the yeast cells may be Saccharomyces cerevisiae, Pichia pastoris, Cyberlindnera jadinii, Candida albicans, or a mixture thereof. In a preferred embodiment, the yeast glucan may be extracted from S. cerevisiae. Preferably, Saccharomyces strain CEN.PK2 has the genotype: MATa / α-ura3-52 / ura3-52-trp1-289 / trp1-289 leu2-3,112 / leu2-3,112 his3 Δ1 / his3 Δ1 MAL2-8C / MAL2-8C SUC2 / SUC2, wherein CEN.PK has a mutation in CYR1(A5627T) corresponding to a K1876M substitution near the end of the catalytic domain in adenylate cyclase, thereby eliminating glucose- and acidification-induced cAMP signaling and delaying loss of glucose-induced stress resistance.
[0013] In one embodiment, the amount of β-glucan can be in the range of 1 to 40% (w / w), preferably in the range of 4 to 25% (w / w), and more preferably in the range of 5 to 10% (w / w).
[0014] In one embodiment, the molecular weight of the β-glucan is in the range of 200 to 800 KDa, preferably in the range of 300 to 600 KDa.
[0015] In one embodiment, the amount of emollient may range from 30-80% (w / w), preferably from 60-80% (w / w).
[0016] In one embodiment, the emollient is squalane.
[0017] In one embodiment, the amount of β-glucan is in the range of 4-10% (w / w), preferably the amount of β-glucan is in the range of 5-7% (w / w), and more preferably the amount of β-glucan is in the range of 5-6% (w / w).
[0018] Another aspect of the present disclosure relates to a topical facial composition for preventing or treating herpes simplex virus infection comprising an emulsion of yeast beta-glucan, the emulsion comprising an emollient, preferably the emollient is selected from squalane, butter, hemp oil, or mixtures thereof, the composition being administered topically to the face, particularly in the form of an anti-herpes lipstick, face stick, lip balm, face balm, or roll-on.
[0019] In one embodiment, the topical facial composition of the present disclosure may further comprise at least one of at least a filler, at least an oil (preferably an essential oil), at least a preservative, at least a dye, at least a fragrance, at least a flavoring, at least a hydrating agent, at least a pH adjuster, at least a stabilizer, a thickener, or a combination thereof.
[0020] In one embodiment, the amount of filler ranges from 10 to 30% (w / w), preferably from 10 to 20% (w / w).
[0021] In one embodiment, the filler is selected from wax, paraffin, beeswax, or mixtures thereof.
[0022] In one embodiment, the preservative is selected from citric acid, phenethyl alcohol, benzoic acid, sorbic acid, salicylic alcohol, tocopherol, or mixtures thereof.
[0023] In one embodiment, the amount of preservative ranges from 0.1 to 2% (w / w), preferably 0.5 to 1% (w / w).
[0024] In one embodiment, the weight ratio of glucan to emollient ranges from 0.5:1 to 1:2, preferably from 1:1 to 1:2.
[0025] In one embodiment, the topical facial composition of the present disclosure may include dyes, fragrances, flavorings, hydrating agents, pH adjusters, stabilizers, thickeners, or combinations thereof.
[0026] Another aspect of the present disclosure relates to a method for obtaining the β-glucan of the present disclosure, the method comprising: obtaining autolyzed yeast cells; extracting dry alkaline glucan of the yeast by adding an alkaline solution to the yeast cells in a solid-liquid extraction and collecting a first pellet; and adding an alcohol solution and an acid solution to the resulting first pellet in a second solid-liquid extraction to obtain a second pellet containing yeast β-glucan. [Brief description of the drawings]
[0027] The following figures provide preferred embodiments to illustrate the present disclosure and should not be considered as limiting the scope of the invention. [Figure 1] Schematic diagram of an embodiment of HaCaT cells infected with HSVI and exposed to glucan for 48 hours. Cell mortality is expressed by comparison with cells infected with HSVI. Acyclovir was used as a positive control. [Diagram 2] FIG. 1 is a schematic diagram of an embodiment of IL-1β, IL-8 and TNF-α cytokine production in macrophages derived from HSVI-infected THP-1 cells. [Diagram 3] FIG. 3(A) is a schematic diagram showing the appearance of glucan powder according to one embodiment, and FIG. 3(B) is a schematic diagram showing a glucan solution (aqueous solution) emulsified with squalane according to one embodiment. [Figure 4] FIG. 1 is a schematic diagram of one embodiment of crystal violet staining of HaCaT cells infected with HS-IV and treated with β-glucan and β-glucan formulated with squalane. [Diagram 5] FIG. 5(A) is a representative graph of β-glucan fluorescence frequency versus intensity in skin section tissue stained with Calcofluor after treatment with Glu-RbM or Glu-RbM / SQ for 2 hours, and FIG. 5(B) is a representative graph of β-glucan fluorescence frequency versus intensity after treatment with Glu-RbM / SQ for 2 hours and 6 hours. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0028] The present disclosure relates to emulsions of yeast β-glucan for the prevention or treatment of herpes simplex virus infection, and in particular to emulsions of yeast β-glucan, wherein the emulsion comprises an emollient, the emollient being selected from squalane, butter, hemp oil, or mixtures thereof.
[0029] The present disclosure relates to emulsions of yeast β-glucan with anti-herpes activity, in particular to topical facial compositions, more particularly lipsticks / face sticks / lip balms or face balms / roll-ons with anti-herpes properties, methods for obtaining same and uses thereof.
[0030] The present disclosure also relates to topical facial compositions, preferably antiherpes active lip or face sticks, antiherpes lip or face balms, or antiherpes roll-ons, comprising β-glucan and to the use of said compositions for the prevention and treatment of lesions of the lips and other areas of the face caused by the human herpes simplex virus.
[0031] The present disclosure relates to lipsticks / lip balms / roll-ons containing β-glucans having anti-herpes activity and thus relates to the preparation of lipsticks / lip balms / roll-ons having anti-herpes properties.
[0032] List of Abbreviations Glu-RbM: Glucan alkaline + organic / acid treatment from spent RebM producing yeast Glu-WT: Glucan from wild-type yeast CEN.PK2 alkaline + organic / acid treatment Wild-type yeast CEN.PK2-Saccharomyces cerevisiae strain. CEN.PK2 genotype: MATa / α-ura3-52 / ura3-52-trp1-289 / trp1-289 leu2-3,112 / leu2-3,112 his3 Δ1 / his3 Δ1 MAL2-8C / MAL2-8C SUC2 / SUC2. CEN.PK harbors a mutation in CYR1(A5627T) corresponding to a K1876M substitution near the end of the catalytic domain in adenylyl cyclase, thus eliminating glucose- and acidification-induced cAMP signaling and delaying the loss of glucose-induced stress resistance. RbM:RebM sweetener molecule HaCaT: human epidermal keratinocytes
[0033] Glucan Extraction and Purification In one embodiment, the inventors extracted glucan from spent yeast engineered to produce the sweetener molecule RebM (RbM). As these strains are genetically modified organisms (GMOs), the inventors have also tested glucan from wild-type Saccharomyces cerevisiae strain CEN.PK2. In one embodiment, yeast glucan was extracted from spent yeast from the production of sweetener molecules. These strains may be genetically modified organisms (GMOs), and glucan from wild-type Saccharomyces cerevisiae strain CEN.PK2 was also extracted. Saccharomyces cerevisiae strain CEN.PK2 genotype: MATa / α-ura3-52 / ura3-52-trp1-289 / trp1-289 leu2-3,112 / leu2-3,112 his3 Δ1 / his3 Δ1 MAL2-8C / MAL2-8C SUC2 / SUC2, CEN.PK harbors a mutation in CYR1(A5627T) corresponding to a K1876M substitution near the end of the catalytic domain in adenylyl cyclase that abrogates glucose- and acidification-induced cAMP signaling and delays the loss of glucose-induced stress resistance.
[0034] In one embodiment, yeast was subjected to a heat treatment to release cellular components, i.e. autolysis, thereby allowing the isolation and purification of glucans present in the insoluble fraction (pellet) of yeast cell wall polysaccharides. After autolysis, the first step in the extraction was initiated by an alkaline treatment, in which an initial solution of 20% (w / v) was prepared using the autolyzed yeast pellet and sodium hydroxide (NaOH 1M) as solvent. This solution was then placed in a water bath at 90°C for 2-4 hours. It was then centrifuged at 8000 rpm for 10 minutes at 4°C and the supernatant was discarded. The resulting pellet was washed three times by centrifugation with deionized water. The washed pellet was resuspended in 50 ml of deionized water and neutralized with hydrochloric acid (HCl 3M) until pH 7. The supernatant was removed by centrifugation and a final wash was performed with the same volume of deionized water. The resulting pellets, containing the insoluble alkaline glucan, were thoroughly homogenized with deionized water and dried by spray drying at an inlet temperature of 110°C and an outlet temperature of 50°C.
[0035] An acid / ethanol extraction was used to remove remaining proteins, lipids and other unwanted compounds. For this extraction, 1 g of dried alkaline glucan was dissolved in 80 ml ethanol (99%) and 1.6 ml HCl 32% (w / v) and placed in an orbital shaker at 50° C. for 4 hours. The pellet was then washed three times, twice with absolute ethanol and once with acetone, suspended in 20 ml of each solvent and centrifuged at 8000 rpm for 10 minutes at 4° C. The purified glucan was dried overnight at 50° C. in a vacuum oven.
[0036] β-glucan protects against HSVI infection The beneficial effects of β-glucans as inflammatory regulators are being actively investigated. They have the ability to induce immune responses by interacting with specific macrophage receptors. Some studies have indicated that β-glucans exhibit antiviral capabilities.
[0037] We tested the antiviral potential of Glu-RbM and Glu-WT extracts in human epidermal keratinocytes (HaCaT) infected with HSVI. 1 × 10 HaCaT cells were cultured in 96-well plates. 5 The cells were then exposed to HSVI at a multiplicity of infection (MOI) of 0.2 in 199V medium for 1 h at 37°C. The medium containing the virus was removed and fresh medium was added alone or supplemented with different glucan concentrations. After 48 h of exposure, Presto blue assay was performed and the results were expressed as percentage cell death compared to cells infected with HSVI. Our results show that Glu-Rb and Glu-WT protect keratinocytes from HSVI infection in a dose-dependent manner (Figure 1). These results were replicated in other cell lines such as macrophages derived from Vero cells and THP-1 cells (data not shown). The same test conditions were applied to evaluate the anti-herpes activity of the emulsions of Example 1 and Example 2.
[0038] β-Glucan stimulates the immune system in HSVI infection In one embodiment, to examine the immunomodulatory effect of β-glucan in HSVI-infected cells, 3.5×10 THP-1 cells were cultured in a 24-well plate. 5 β-glucans were seeded at 1000 cells / ml and exposed to phorbol-12-myristate-13-acetate (PMA, 50 nM) for 72 h to induce macrophage differentiation. Cells were then infected with HSVI and treated with the different glucans for 48 h. Immunomodulatory activity was assessed by flow cytometry using LEGENDplex™ (BioLegend) bead-based immunoassays. The results showed that β-glucan induced the expression of IL-1β, IL-8, and TNF-α in HSVI cells, suggesting that β-glucan stimulates the immune system to combat HSVI infection (Figure 2).
[0039] β-Glucan formulated with emollients retains anti-herpes activity In one embodiment, β-glucans are insoluble and therefore must be solubilized for use during preparation. To achieve this, the glucans are mixed with an emollient such as squalane in a 1:1 (w / w) ratio (Figure 3). Other agents include squalane, butter, hemp oil, or mixtures thereof, preferably squalane.
[0040] To verify whether the prepared β-glucan retained its anti-herpes ability, HaCaT cells were cultured at 3 × 10 5 Cells were seeded at 1000 x glucan / well. The cells were then infected with HSVI and treated with β-glucan for 48 h. The cells were then washed, fixed with 4% paraformaldehyde (PFA) for 20 min, and stained with 0.05% crystal violet. After extensive washing and air drying, microscopic images of the various conditions were taken with an inverted microscope (Figure 4). The results show that the prepared glucan can prevent HSVI-induced cell death as well as β-glucan alone.
[0041] Emollients increase the permeability of glucan through the skin In one embodiment, the permeability is improved by preparing the β-glucan with an emollient such as squalane. As β-glucan is insoluble, it does not easily penetrate the skin when it comes into contact with it and therefore does not interact with the skin cells. This results in a decrease in β-glucan activity. However, when prepared with squalane, β-glucan is more likely to penetrate the skin. To test the permeability of β-glucan, skin grafts were exposed to β-glucan and treated with the Franz permeation cell method using β-glucan prepared with squalane. The skin grafts were processed for histological analysis. Briefly, the skin grafts were subjected to four main steps: fixation with PFA 4%, dehydration, clearing, and finally embedding in paraffin. Histological sections (4 μm) were stained with hematoxylin & eosin for histological evaluation and stained with fluorescent dyes specific for β-glucan, calcofluor (1:1 potassium hydroxide). Microscopic fluorescence images of the samples stained with Calcofluor were evaluated by intensity / frequency analysis. The results show that after 2 hours of exposure, Glu-RbM / SQ is more widely distributed (improved frequency) in the skin than Glu-RbM alone (Figure 5A). After 6 hours, squalane improved the frequency (distribution) of glucan in the skin tissue compared to after 2 hours (Figure 5B).
[0042] Example 1: Emulsion of β-glucan In Example 1, 550KDa and 5% (w / w) β-glucan; 80% (w / w) squalane, 1% (w / w) preservative, Emulsions were prepared with up to 100% (w / w) water.
[0043] Example 2: Emulsion of β-glucan In Example 2, 400KDa and 5% (w / w) β-glucan; 80% (w / w) squalane, 1% (w / w) preservative, Emulsions were prepared with up to 100% (w / w) water.
[0044] [Table 1]
[0045] Example 3: Incorporation of β-glucan into a lipstick balm In one embodiment, to incorporate β-glucan into a formulation for use in a lipstick, lip balm, or roll-on application, the following composition was developed with the weight percentages shown below. Structural agent (or filler): 10-20% (w / w) Emollients: 60-80% (w / w) Glucan: 1-40% (w / w) Preservative: 0.11% (w / w)
[0046] In one embodiment, waxes were used as structuring or fillers, specifically soy wax, rice wax, and candelilla wax. Emollients act as moisturizers to smooth and hydrate the skin and were included in the form of butters such as shea butter, and cocoa butter, and oils such as coconut oil, sweet almond oil, and squalane. The yeast beta-glucan of the present disclosure (5-25% w / w) was added to the emulsion with squalane to improve skin penetration. Tocopherol was added as a preservative to ensure stability and prevent lipid degradation. This preparation can be considered vegan.
[0047] In this specification, use of the term "comprising" is intended to specify the presence of the stated features, integers, steps, components, but it is to be understood that it does not exclude the presence or addition of one or more other features, integers, steps, components, or groups thereof.
[0048] In the claims, the singular form of each element or feature is used to include the plural form, and vice versa, unless expressly excluded. For example, the singular form "(a) β-glucan" or "the β-glucan" also includes the plural form "β-glucan" or "these β-glucans", and vice versa. In the claims, the articles "a", "an", and "the" may mean one or more, unless otherwise indicated or otherwise clear from the context. In each claim or specification, when "or" is used between one or more members of a group, it is considered to be satisfied if one member, two or more members, or all members of the group are present, used, or relevant in a given product or process, unless otherwise indicated or otherwise clear from the context. The present invention includes embodiments in which only one member of the group is present, used, or relevant in a given product or process. The invention also includes embodiments in which more than one, or all of the group members are present in, employed in, or otherwise relevant to a given product or process.
[0049] Moreover, it is to be understood that the present invention encompasses all modifications, combinations, and permutations of one or more limitations, elements, clauses, descriptive terms, etc., introduced into another claim based on one or more claims or relevant portions of the specification. For example, any claim that refers to another claim can be modified to include one or more limitations in any other claim that depends from the same base claim.
[0050] Furthermore, when a composition is recited in the claims, it is to be understood that unless otherwise indicated or a contradiction or inconsistency would be apparent to one of ordinary skill in the art, methods of using the composition for any of the purposes disclosed herein are included, and methods of making the composition according to any of the manufacturing methods disclosed herein or other methods known in the art are included.
[0051] When ranges are specified, the endpoints are included. Moreover, unless otherwise indicated or apparent from the context and / or the understanding of one of ordinary skill in the art, values expressed as ranges can assume any particular value within a stated range in different embodiments of the invention, to the tenth of the unit of the lower limit of the range, unless otherwise clearly indicated by the context and / or the understanding of one of ordinary skill in the art. It is also understood that unless otherwise indicated or apparent from the context and / or the understanding of one of ordinary skill in the art, values expressed as ranges can assume any subrange within the given range, with the endpoints of the subranges being expressed to the same degree of precision as the tenth of the unit of the lower limit of the range.
[0052] The present disclosure is in no way limited to the described embodiments, and those skilled in the art will envision many possibilities for modifying it.
[0053] The above-described embodiments can be combined.
[0054] The following claims further present certain embodiments of the present disclosure.
Claims
1. 1. An emulsion of yeast β-glucan for the prevention or treatment of herpes simplex virus infection, said emulsion comprising 30-80% (w / w) of an emollient; The yeast β-glucan emulsion is an antiviral agent; A yeast β-glucan emulsion, wherein the amount of said yeast β-glucan is in the range of 4-25% (w / w).
2. 2. The yeast β-glucan emulsion of claim 1, wherein the emollient is selected from squalane, butter, hemp oil, or a mixture thereof, preferably squalane.
3. 3. An emulsion of yeast β-glucan according to claim 2 for use in the prevention and treatment of lip diseases or human herpes virus on the lips or other areas of the face.
4. 4. The yeast β-glucan emulsion for use according to claim 3, wherein said emulsion is administered in the form of a topical composition for the face, preferably in the form of an anti-herpes lipstick, face stick, lip or face balm, or a roll-on.
5. The yeast β-glucan emulsion for use according to claim 4, wherein said yeast β-glucan is insoluble in water, preferably said yeast β-glucan is a natural β-glucan.
6. 6. An emulsion of yeast β-glucan for use according to any of claims 1 to 5, wherein the amount of yeast β-glucan is in the range of 4-10% (w / w), preferably in the range of 5-10% (w / w).
7. 7. An emulsion of yeast β-glucan for use according to any of claims 1 to 6, wherein the amount of yeast β-glucan is in the range of 4-7% (w / w), preferably in the range of 5-6% (w / w).
8. 8. An emulsion of yeast β-glucan for use according to any of claims 1 to 7, wherein the amount of yeast β-glucan is in the range of 4-6% (w / w), preferably 5-6% (w / w).
9. An emulsion of yeast β-glucan for use according to any of claims 1 to 8, wherein the molecular weight of the yeast β-glucan is in the range of 200 to 800 KDa.
10. 10. An emulsion of yeast β-glucan for use according to any of claims 1 to 9, wherein the molecular weight of the yeast β-glucan is in the range of 300 to 600 KDa.
11. A yeast β-glucan emulsion for use according to any of claims 1 to 10, wherein the amount of said emollient is in the range of 60-80% (w / w).
12. A topical facial composition comprising an emulsion of yeast beta-glucan, said emulsion including an emollient for the prevention or treatment of herpes simplex virus infection, said composition being administered topically to the face, in particular in the form of an anti-herpes lipstick, or face stick, or lip or face balm, or roll-on.
13. 13. The topical facial composition of claim 12, wherein the emollient is selected from squalane, butter, hemp oil, or mixtures thereof.
14. 14. A topical facial composition according to any of claims 1 to 13, further comprising at least one of at least a filler, at least an oil (preferably an essential oil), at least a preservative, at least a dye, at least a fragrance, at least a flavoring, at least a hydrating agent, at least a pH adjuster, at least a stabilizer, a thickener, or a combination thereof.
15. 15. A topical facial composition according to any of claims 1 to 14, wherein the filler is selected from wax, paraffin, beeswax, or mixtures thereof, and / or the preservative is selected from citric acid, phenethyl alcohol, benzoic acid, sorbic acid, salicylic alcohol, tocopherol, or mixtures thereof.
16. 16. A topical facial composition according to claim 15, wherein the amount of said filler is in the range of 10-30% (w / v), preferably in the range of 10-20% (w / v) and / or the amount of said preservative is in the range of 0.1-2% (w / w), preferably in the range of 0.5-1% (w / w).
17. 17. A topical lipstick composition according to any preceding claim, wherein the weight ratio of said yeast beta-glucan to said emollient is in the range of 0.5:1 to 1:2, preferably in the range of 1:1 to 1:
2.
18. obtaining autolyzed yeast cells; extracting the dry alkaline glucan of the yeast by adding an alkaline solution to the yeast cells and recovering a first pellet by solid-liquid extraction; adding an alcohol solution and an acid solution to the obtained first pellet in a second solid-liquid extraction to obtain a second pellet containing yeast β-glucan; A method for obtaining the yeast β-glucan according to any one of claims 1 to 17, comprising:
